

Sup. IIDS
PATENT
5.14.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: ANNA P. CATANIA, *et al.*

APPLICATION NO.: 09/533,341

FILED: MARCH 23, 2000

FOR: **ANTIMICROBIAL AND ANTI-INFLAMMATORY
PEPTIDES FOR USE IN HUMAN
IMMUNODEFICIENCY VIRUS**

EXAMINER: JEFFREY S. PARKIN

ART UNIT: 1648

CONF. NO.: 9950

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

1. Timing of Submission

This information is being filed *after* the submission of a Request for Continued Examination.

2. Cited Information

Copies of the following references are enclosed:

All cited references
 References marked by asterisks
 The following:

Copies of the following references can be found in parent U.S. Application No. :

All cited references
 References marked by asterisks
 The following:

Certificate of Mailing

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

March 17, 2003
Date of Deposit

Debbie Gilbert
Debbie Gilbert

The following references are not in English. For each such reference, the undersigned has enclosed: (i) a translation of the reference; (ii) a copy of a communication from a foreign patent office or International Searching Authority citing the reference; (iii) a copy of a reference which appears to be an English-language counterpart; or (iv) an English-language abstract for the reference prepared by a third party. Applicant has not verified that the translation, English-language counterpart or third-party abstract is an accurate representation of the teachings of the non-English reference, though, and reserves the right to demonstrate otherwise.

All cited references
 References marked by ampersands
 The following:

3. Effect of Information Disclosure Statement (37 CFR 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-0665.

[Continued on the next page]


5. Patent Term Adjustment (37 CFR 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. §1.704(d).

Respectfully submitted,

Perkins Coie LLP

Date: 3/15/07


Michael J. Wise
Registration No. 34,047

Correspondence Address:

Customer No. 34055
Perkins Coie LLP
P.O. Box 1208
Seattle, WA 98111-1208
Phone: (310) 788-9900
Fax: (310) 788-3399

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	09/533,341
				Confirmation Number	
				Filing Date	March 23, 2000
				First Named Inventor	Anna P. Catania
				Group Art Unit	
				Examiner Name	Jeffrey S. Parkin
Sheet	1	of	2	Attorney Docket No.	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).